Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

107.49 +0.55 (+0.51%)
Delayed Quote Updated: 9:33 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,452
Open 107.07
Bid (Size) 107.13 (100)
Ask (Size) 107.98 (100)
Prev. Close 106.94
Today's Range 106.65 - 107.64
52wk Range 61.23 - 116.84
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
+52.9%
+52.9%
1 Month
-0.2%
-0.2%
3 Month
+35.3%
+35.3%
6 Month
+66.7%
+66.7%
1 Year
+43.4%
+43.4%

More News

Read More
News headline image
1 Cash-Producing Stock to Target This Week and 2 We Question
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗
Via Chartmill
News headline image
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
Via The Motley Fool
Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗
Via Chartmill
News headline image
1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
Via StockStory
Topics Fraud
News headline image
3 Market-Beating Stocks for Long-Term Investors
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Avoid
Via StockStory
Topics Economy
News headline image
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
Via Chartmill
News headline image
Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
Via StockStory
Topics Earnings Intellectual Property
News headline image
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Via StockStory
News headline image
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
Via StockStory
Topics Artificial Intelligence
News headline image
1 Profitable Stock to Research Further and 2 We Ignore
Via StockStory
News headline image
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
Via StockStory
News headline image
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
Via StockStory
News headline image
3 Growth Stocks Set to Flourish
Via StockStory
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
Via StockStory
Topics Energy
News headline image
1 Value Stock Worth Investigating and 2 Facing Headwinds
Via StockStory
News headline image
2 Reasons to Like HALO and 1 to Stay Skeptical
Via StockStory
Topics Stocks
News headline image
1 Surging Stock for Long-Term Investors and 2 We Brush Off
Via StockStory

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 107.49
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 10/02/26 09:33 AM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 15.30B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.